1-10 of 10
Jeffrey S. Miller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Shernan G. Holtan, Constanza Savid-Frontera, Kelly Walton, Anne A. Eaton, Connor Demorest, Andrea Hoeschen, Ling Zhang, Kayla Reid, Tony Kurian, Zena Sayegh, Estefania Julia, Joseph Maakaron, Veronika Bachanova, Najla El Jurdi, Margaret L. MacMillan, Daniel J. Weisdorf, Martin Felices, Jeffrey S. Miller, Bruce R. Blazar, Marco L. Davila, Brian C. Betts
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1114–1124.
https://doi.org/10.1158/1078-0432.CCR-22-2837
Published: 14 March 2023
View article titled, Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Open the PDF for Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, Jeffrey S. Miller, Sylvia M. Lee, Ann W. Silk, Shernan G. Holtan, Andreanne M. Lacroix, Steven P. Fling, Judith C. Kaiser, Jack O. Egan, Monica Jones, Peter R. Rhode, Amy D. Rock, Martin A. Cheever, Hing C. Wong, Marc S. Ernstoff
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (22): 5552–5561.
https://doi.org/10.1158/1078-0432.CCR-18-0945
Published: 15 November 2018
View article titled, Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML

Andreas T. Björklund, Mattias Carlsten, Ebba Sohlberg, Lisa L. Liu, Trevor Clancy, Mohsen Karimi, Sarah Cooley, Jeffrey S. Miller, Monika Klimkowska, Marie Schaffer, Emma Watz, Kristina Wikström, Pontus Blomberg, Björn Engelbrekt Wahlin, Marzia Palma, Lotta Hansson, Per Ljungman, Eva Hellström-Lindberg, Hans-Gustaf Ljunggren, Karl-Johan Malmberg
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1834–1844.
https://doi.org/10.1158/1078-0432.CCR-17-3196
Published: 12 April 2018
View article titled, Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Open the PDF for Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E.K. Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary L. Disis, Judith C. Kaiser, Martin A. Cheever, Howard Streicher, Steven P. Creekmore, Thomas A. Waldmann, Kevin C. Conlon
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1525–1535.
https://doi.org/10.1158/1078-0432.CCR-17-2451
Published: 02 April 2018
View article titled, A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors in another window
Journal Articles

Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?

Martin Felices, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5161–5163.
https://doi.org/10.1158/1078-0432.CCR-16-1582
Published: 31 October 2016
View article titled, Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
Open the PDF for Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise? in another window
Journal Articles

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Daniel A. Vallera, Martin Felices, Ron McElmurry, Valarie McCullar, Xianzheng Zhou, Joerg Uwe Schmohl, Bin Zhang, Alexander J. Lenvik, Angela Panoskaltsis-Mortari, Michael R. Verneris, Jakub Tolar, Sarah Cooley, Daniel J. Weisdorf, Bruce R. Blazar, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (14): 3440–3450.
https://doi.org/10.1158/1078-0432.CCR-15-2710
Published: 14 July 2016
View article titled, IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33<sup>+</sup> Targets While Also Inducing Persistence, <em>In Vivo</em> Expansion, and Enhanced Function
Open the PDF for IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33<sup>+</sup> Targets While Also Inducing Persistence, <em>In Vivo</em> Expansion, and Enhanced Function in another window
Includes: Supplementary data
Journal Articles

Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies

Veronika Bachanova, Arthur E. Frankel, Qing Cao, Dixie Lewis, Bartosz Grzywacz, Michael R. Verneris, Celalettin Ustun, Aleksandr Lazaryan, Brian McClune, Erica D. Warlick, Hagop Kantarjian, Daniel J. Weisdorf, Jeffrey S. Miller, Daniel A. Vallera
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1267–1272.
https://doi.org/10.1158/1078-0432.CCR-14-2877
Published: 12 March 2015
View article titled, Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies
Open the PDF for Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies in another window
Journal Articles

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Andres Wiernik, Bree Foley, Bin Zhang, Michael R. Verneris, Erica Warlick, Michelle K. Gleason, Julie A. Ross, Xianghua Luo, Daniel J. Weisdorf, Bruce Walcheck, Daniel A. Vallera, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (14): 3844–3855.
https://doi.org/10.1158/1078-0432.CCR-13-0505
Published: 15 July 2013
View article titled, Targeting Natural Killer Cells to Acute Myeloid Leukemia <em>In Vitro</em> with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Open the PDF for Targeting Natural Killer Cells to Acute Myeloid Leukemia <em>In Vitro</em> with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition in another window
Journal Articles

First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer

Arkadiusz Z. Dudek, Carla Yunis, Lester I. Harrison, Sandeep Kumar, Ronald Hawkinson, Sarah Cooley, John P. Vasilakos, Kevin S. Gorski, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7119–7125.
https://doi.org/10.1158/1078-0432.CCR-07-1443
Published: 03 December 2007
View article titled, First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer
Open the PDF for First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer in another window
Journal Articles

Trastuzumab and Interleukin-2 in HER2-positive Metastatic Breast Cancer: A Pilot Study

Tanya Repka, Elena G. Chiorean, Juliette Gay, Katherine E. Herwig, Virginia K. Kohl, Douglas Yee, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2440–2446.
Published: 01 July 2003
View article titled, Trastuzumab and Interleukin-2 in HER2-positive Metastatic Breast Cancer: <subtitle>A Pilot Study</subtitle>
Open the PDF for Trastuzumab and Interleukin-2 in HER2-positive Metastatic Breast Cancer: <subtitle>A Pilot Study</subtitle> in another window